Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Evaluating the biological efficacy of clopidogrel: genotype or phenotype?].

Revue medicale suisse - 10 Feb 2010

Fontana Pierre, Bonvini Robert F, Roffi Marco, Boehlen Françoise, Reber Guido, de Moerloose Philippe, Reny Jean-Luc

Abstract excerpt

Clopidogrel has a known biological variability that has been consistently associated with recurrence of coronary ischemic events in clinical studies. Among the tests that are currently available, quantification of the phosphorylation status of the vasodilator phosphoprotein (VASP assay) is probably the most specific assay to evaluate the inhibition of the P2Y12 receptor by clopidogrel. A genetic polymorphism of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Microfilament Proteins
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Cell Adhesion Molecules

Share to Clopidogrel

Share to Cytochrome P-450 CYP2C19

Share to Platelet Aggregation Inhibitors

Share to Ticlopidine

Source

Identifiers

PMID: 20218180

Genes

VASP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Evaluating the biological efficacy of clopidogrel: genotype or phenotype?].PMID 20218180Read ↗

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.Semantic proximity Read ↗

Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.Semantic proximity Read ↗

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrelSemantic proximity Read ↗

Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery DiseaseSemantic proximity Read ↗

Most Recent Evidence Behind Aggregometry and Genotyping Methods as Platelet Function Testing for Tailored Anti-Platelet Treatment Among PCI Patients.Semantic proximity Read ↗

Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.Semantic proximity Read ↗

Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.Semantic proximity Read ↗

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.Semantic proximity Read ↗

Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.Semantic proximity Read ↗

Clopidogrel and genetic testing: is it necessary for everyone?Semantic proximity Read ↗

Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting.Semantic proximity Read ↗

Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.